ProQR Q3 revenue misses estimates, reports net loss

ProQR Therapeutics NV

06/11/2025 12:07

Overview

ProQR Q3 revenue missed analyst expectations

Company reported a net loss of €11 mln for Q3 2025

ProQR received CTA authorization for Phase 1 trial of AX-0810

Outlook

ProQR expects initial safety data for AX-0810 by end of 2025

Target engagement data for AX-0810 expected in H1 2026

Result Drivers

CASH POSITION - Strong cash position provides runway into mid-2027, supporting pipeline and partnership activities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
EUR 2.88 mln
EUR 4.36 mln (7 Analysts)
Q3 EPS
-EUR 0.10
Q3 Net Income
-EUR 11.01 mln
Q3 Basic EPS
-EUR 0.10
Q3 Operating Income
-EUR 11.28 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for ProQR Therapeutics NV is $8.50, about 72% above its November 5 closing price of $2.38

Press Release: ID:nGNE4ZCg56

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)